ERRATA

PEDIATRICS ◽  
1985 ◽  
Vol 76 (2) ◽  
pp. 298-298
Keyword(s):  
Single Dose ◽  
Urinary Tract ◽  
Response To Therapy ◽  
Female Adolescents ◽  
Specific Response ◽  
Adolescent Population ◽  
Therapeutic Trials ◽  
Tract Infections ◽  
Current Guidelines ◽  
Single Dose Treatment

In the article, "Single-Dose Versus Conventional Therapy of Urinary Tract Infections in Female Adolescents" by Fine and Jacobson (Pediatrics 1985;75:916-920), the last sentence of the first paragraph should read: Although adolescents have been included in the study samples of many therapeutic trials, their age-specific response to therapy has never been isolated, and no current guidelines exist regarding single-dose treatment in the adolescent population.

Single-dose treatment of uncomplicated urinary tract infections in children

1984 ◽  
Vol 13 (9) ◽  
pp. 705-708 ◽  
Author(s):  
Gary E Stahl ◽  
Paul Topf ◽  
Gary R Fleisher ◽  
Michael E Norman ◽  
Howard W Rosenblum ◽  
...  
Keyword(s):  
Single Dose ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Dose Treatment ◽  
Tract Infections ◽  
Single Dose Treatment

Single-Dose Versus Conventional Therapy of Urinary Tract Infections in Female Adolescents

PEDIATRICS ◽  
1985 ◽  
Vol 75 (5) ◽  
pp. 916-920 ◽  
Author(s):  
Joan S. Fine ◽  
Marc S. Jacobson
Keyword(s):  
Single Dose ◽  
Urinary Tract ◽  
Conventional Treatment ◽  
Dose Group ◽  
Female Adolescents ◽  
Cure Rate ◽  
Group V ◽  
Conventional Dose ◽  
Single Dose Treatment

A randomized, prospective study was done to assess the efficacy of single-dose v conventional treatment of acute urinary tract infection (UTI) in female adolescents. Thirty-one 12- to 18-year-old female adolescents with symptoms of an acute UTI and a urine culture with greater than 105 organisms were treated with amoxicillin, either as a 3.0-g single dose or 250-mg three times daily for ten days. Urine cultures obtained three days after completing therapy in each group, showed bacteriologic cure rate of 69% (11/16) with single-dose treatment compared with a cure rate of 87% (13/15) in the conventional treatment group (P = .23). When patients with resistant organisms were excluded, the cure rate was 85% in both groups. Complete symptom resolution in less than two days after commencing treatment occurred in 36% of single-dose group v none of the patients in the conventional-dose group. The finding has not been previously reported in single-dose trials. Candida vaginitis occurred in 20% of the conventional-dose group v none of the single-dose group. All patients in the single-dose group kept their first scheduled follow-up appointment, whereas 40% in the conventional group required reminders and rescheduling. Perfect compliance with the medication regimen was reported by 27% of the patients taking ten days of medicine. Although single-dose cure rates may not be superior to conventional-dose rates, the advantages of single-dose treatment include increased compliance with medication and follow-up, decreased side effects, and more rapid resolution of symptoms.

Sign in / Sign up

Export Citation Format

Share Document